Cost-effectiveness of lurasidone vs quetiapine extended-release (XR) in patients with bipolar depression

References

• National Institute of Mental Health. Bipolar disorder. Rockville, MD: U.S. Department of Health and Human Services, 2012. http://www.nimh.nih.gov/health/publications/bipolar-disorder-in-adults/Bipolar_Disorder_Adults_CL508_144295.pdf. Accessed May 2015
   Google Scholar
• Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. Arch Gen Psychiatry 2007;64:543-52
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Frank E, Scott JA, et al. Metabolic syndrome in bipolar disorder, findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005;7:424-30
   PubMed Web of Science ®Google Scholar
• Vancampfort D, Vansteelandt K, Correl CU, et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry 2013;170:265-74
   PubMed Web of Science ®Google Scholar
• Huxley N, Baldessarini RJ. Disability and its treatment in bipolar disorder patients. Bipolar Disord 2007;9:183-96
   PubMed Web of Science ®Google Scholar
• Gardner HH, Kleinman NL, Brook RA, et al. The economic impact of bipolar disorder in an employed population from an employer perspective. J Clin Psychiatry 2006;67:1209-18
   PubMed Web of Science ®Google Scholar
• Kupka RW, Altshuler LL, Nolen WA, et al. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord 2007;9:531-5
   PubMed Web of Science ®Google Scholar
• Judd L, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-7
   PubMed Web of Science ®Google Scholar
• Judd L, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003;60:261-9
   PubMed Web of Science ®Google Scholar
• Fu AZ, Krishnan AA, Harris SD. The burden of depression patients with bipolar disorder. Abstract NR556. Presented at: American Psychiatric Association 157th Annual Meeting; May 1-6, 2004; New York, NY
   Google Scholar
• Perlick DA, Rosenheck RA, Clarkin JF, et al. Symptoms predicting inpatient service use among patients with bipolar affective disorder. Psychiatr Serv 1999;50:806-12
   PubMed Web of Science ®Google Scholar
• Altshuler LL, Gitlin MJ, Mintz J, et al. Subsyndromal depression is associated with functional impairment in patients with bipolar disorder. J Clin Psychiatry 2002;63:807-1
   PubMed Web of Science ®Google Scholar
• Dilsaver SC. An estimate of the minimum economic burden of bipolar I and II disorders in the United States: 2009. J Affect Disord 2011;129:79-83
   PubMed Web of Science ®Google Scholar
• National and regional estimates on hospital use for all patients from the HCUP Nationwide Inpatient Sample (NIS), 2011. Rockville, MD: AHRQ. http://hcupnet.ahrq.gov/HCUPnet.jsp. Accessed December 4, 2013
   Google Scholar
• Kleinman L, Lowin A, Flood E, et al. Costs of bipolar disorder. Pharmacoeconomics 2003;21:601-22
   PubMed Web of Science ®Google Scholar
• Goetzel RZ, Hawkins K, Ozminkowski RJ, et al. The health and productivity cost burden of the “top 10” physical and mental health conditions affecting six large U.S. employers in 1999. J Occup Environ Med 2003;45:5-14
   PubMed Web of Science ®Google Scholar
• Seroquel XR [package insert]. Wilmington, DE: AstraZeneca, 2013
   Google Scholar
• Latuda [package insert]. Marlborough, MA: Sunovion Pharmaceuticals Inc., 2013
   Google Scholar
• Begley CE, Annegers JF, Swann AC, et al. The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. Pharmacoeconomics 2001;19:483-95
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014;171:160-8
   PubMed Web of Science ®Google Scholar
• Suppes T, Datto C, Minkwitz M, et al. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord 2010;121:106-15
   PubMed Web of Science ®Google Scholar
• Leclerc E, Mansur RB, Brietzke E. Determinants of adherence to treatment in bipolar disorder: a comprehensive review. J Affect Disord 2013;149:247-52
   PubMed Web of Science ®Google Scholar
• Red Book Online®. Chicago, IL: Truven Health Analytics, 2014. http://www.micromedexsolutions.com. Accessed June 11, 2014
   Google Scholar
• Data on file. Truven Health MarketScan® Commercial and Medicare Supplemental Analysis for bipolar depression. Marlborough, MA: Sunovion Pharmaceuticals Inc., 2013
   Google Scholar
• McIntyre RS, Fallu A, Konarski JZ. Measureable outcomes in psychiatric disorders: remission as a marker of wellness. Clin Ther 2006;28:1882-91
   PubMed Web of Science ®Google Scholar
• Unützer J, Patrick DL, Simon G, et al. Depressive symptoms and the cost of health services in HMO patients aged 65 years and older. A 4-year prospective study. JAMA 1997;277:1618-23
   PubMed Web of Science ®Google Scholar
• Simon G, Ormel J, VonKorff M, et al. Health care costs associated with depressive and anxiety disorders in primary care. Am J Psychiatry 1995;152:352-7
   PubMed Web of Science ®Google Scholar
• Fleurence FL, Chatterton ML, Dixon JM, et al. Economic outcomes associated with atypical antipsychotics in bipolar disorder: a systematic review. Prim Care Companion J Clin Psychiatry 2007;9:419-28
   PubMedGoogle Scholar
• Plosker GL. Quetiapine: a pharmacoeconomic review of its use in bipolar disorder. Pharmacoeconomics 2012;30:611-31
   PubMed Web of Science ®Google Scholar
• Fajutrao L, Paulsson B, Liu S, et al. Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis. Clin Ther 2009;31:1456-68
   PubMed Web of Science ®Google Scholar
• Woodward TC, Tafesse E, Quon P, et al. Cost-effectiveness of quetiapine with lithium of divalproex for maintenance treatment of bipolar I disorder. J Med Econ 2009;12:259-68
   PubMedGoogle Scholar
• Woodward TC, Tafesse E, Quon P, et al. Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder. Pharmacoeconomics 2010;28:751-64
   PubMed Web of Science ®Google Scholar
• Ekman M, Lindgren P, Miltenburger C, et al. Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode. Pharmacoeconomics 2012;30:513-30
   PubMed Web of Science ®Google Scholar